ProfileGDS5678 / 1419032_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 56% 53% 74% 59% 48% 52% 59% 59% 53% 57% 51% 54% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2607350
GSM967853U87-EV human glioblastoma xenograft - Control 23.4275656
GSM967854U87-EV human glioblastoma xenograft - Control 33.3146953
GSM967855U87-EV human glioblastoma xenograft - Control 44.9669474
GSM967856U87-EV human glioblastoma xenograft - Control 53.5210459
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2488248
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3409252
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5599159
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5203859
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2793553
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.432157
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2043951
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3608654
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3024253